Chronic Conditions
Invasive Candida
Invasive candidiasis and candidemia often require extended IV antifungal therapy after hospital discharge. Once a patient is medically stable, TwelveStone Health Partners helps continue treatment through outpatient infusion services or home infusion support.Our clinical team coordinates with hospital physicians, manages insurance verification, and helps patients transition safely from inpatient care to ongoing therapy. With more than 30 infusion centers across the Southeast, we make it easier to continue treatment while focusing on recovery.
Invasive Candida Medications
Why Invasive Candida Infections Often Require Infusion Therapy
Invasive Candida infections affect the bloodstream or internal organs and require prompt medical treatment. Because these infections can become serious quickly, patients are often started on intravenous antifungal medications in the hospital before transitioning to outpatient therapy when clinically appropriate.
Patients who commonly require ongoing antifungal infusion therapy include those with:
- Recent abdominal surgery or organ transplantation
- Weakened immune systems
- Prolonged hospital stays
- Central venous catheter-related infections
- Extended antibiotic exposure
After stabilization, patients may continue treatment through an outpatient infusion program. TwelveStone works directly with hospital discharge teams and prescribing physicians to coordinate therapy, schedule appointments, and maintain continuity of care throughout treatment.
Antifungal Infusion Therapies Used for Invasive Candida Infections
Common first-line therapies include echinocandins such as caspofungin, micafungin, and anidulafungin. These medications help control fungal infections while allowing patients to continue treatment outside the hospital when appropriate.
Targeted Alternative Therapies
Once a patient is stable, healthcare providers may adjust the medication based on clinical needs:
- Fluconazole serves as a step-down option for stable patients with susceptible isolates.
- Amphotericin B is reserved for resistant strains or cases of drug intolerance.
- Rezafungin offers a once-weekly dosing option that simplifies outpatient scheduling, subject to clinical approval.
Treatment plans are adjusted based on laboratory findings, medication response, and overall clinical progress. TwelveStone coordinates these therapies under physician supervision to help patients safely continue care after hospital discharge.

Clinical Monitoring and the Transition to Outpatient Care
Transitioning from hospital to outpatient care requires structured monitoring to confirm the infection is controlled. Physicians follow a standardized protocol before discharging patients for continued therapy.
- Stabilization and IV therapy in the hospital.
- Regular blood cultures to document clearance.
- Evaluation to rule out deep-seated complications.
- Discharge to a structured outpatient plan.
Uncomplicated infections generally require treatment for at least two weeks after symptoms improve and blood cultures are negative.
More complex infections may require longer therapy and additional monitoring. Depending on your condition, physicians may recommend eye exams, echocardiograms, or removal of infected central lines before completing treatment.
TwelveStone Health Partners coordinates this transition to safely continue your invasive candida disease infusion treatment. We manage scheduling, communicate with specialists, and monitor every session.

What to Expect During Outpatient IV Antifungal Therapy
Hospital physicians determine when you can transition to outpatient invasive candida disease infusion treatment. Care proceeds through either scheduled visits to an infusion center or home infusion with nursing support.
TwelveStone coordinators work directly with your discharge planning team to schedule start dates and confirm your prescribed medication, such as daily echinocandins or weekly rezafungin.
Caregivers help manage daily logistics and safety protocols based on the required access:
- IV access: Short courses use a peripheral IV, while longer treatments require a PICC or central line.
- Daily care: Caregivers perform routine flushes, keep dressings dry, and monitor for redness or fever.
- Lab monitoring: Routine blood draws are scheduled to track liver and kidney function.
Patients can receive care at one of TwelveStone’s 30+ infusion centers located throughout Tennessee, Kentucky, Georgia, Mississippi, and Virginia, helping reduce travel burdens while maintaining access to specialized infusion services.
Navigating Insurance and Coverage for IV Antifungal Therapy
IV antifungals for invasive candidiasis typically require benefits verification and prior authorization, especially for specialty medications in outpatient settings. To avoid care delays, TwelveStone Health Partners has dedicated financial counselors to handle the administrative process.
Our care coordinators work with your insurance provider and prescribing clinical team to verify benefits, coordinate prior authorization paperwork, and explore copay assistance.
This support helps clarify expected out-of-pocket costs before your invasive candida disease infusion treatment begins. Because coverage varies by plan, medical indication, and site of care, starting verification early is recommended. Patients can review our patient resources page to understand paperwork expectations.

Your Partner in Invasive Candida Infusion Therapy
TwelveStone Health Partners helps patients safely continue invasive candida disease infusion treatment after hospital discharge through outpatient infusion centers and home infusion services.
Our PharmD-led clinical team coordinates with physicians, manages insurance requirements, and provides ongoing clinical support throughout therapy. With more than 30 infusion centers across the Southeast, we make it easier to access specialized infusion care while focusing on recovery.
Organizational Resources

The Centers for Disease Control and Prevention’s (CDC) Emerging Infections Program (EIP) monitors Candida bloodstream infections in certain areas. The CDC also collects data on healthcare-associated infections through the National Healthcare Safety Network (NHSN).
GLASS started a global collaborative effort to compile available data on invasive fungal infections, including Candida spp. Although less known to the general public, fungi are major causes of human disease and death, and resistance to antifungal medications is a growing problem, similar to antibiotic drugs.

The Infectious Diseases Society of America is a medical association representing physicians, scientists, and other healthcare professionals who specialize in infectious diseases.













